
PRVB: Three Key Takeaways From The FDA Delay
Here are three key takeaways from the FDA’s response to Provention Bio (PRVB)’s BLA application for teplizumab…
Here are three key takeaways from the FDA’s response to Provention Bio (PRVB)’s BLA application for teplizumab…
Here’s what to expect this week from Provention Bio (PRVB) as the FDA’s original PDUFA date hits on Friday…
Provention Bio (PRVB) announced the FDA needs more PK/PD data. Here’s why I’m buying more on this pullback…
Provention Bio (PRVB) announced an offering after the bell yesterday, on a day teh stock hit a 52-week high. Here’s what I plan to do…
Provention Bio (PRVB) successfully priced a $100 million offering. Here are all the details, along with three key data takeaways from the ADA meeting…